Dr Darrin M Disley Obe Email and Phone Number
Dr Darrin M Disley Obe work email
- Valid
- Valid
- Valid
- Valid
- Valid
Dr Darrin M Disley Obe personal email
Dr Darrin M Disley Obe phone numbers
Have started, grown and/or invested in >40 life science, technology and social enterprises closing over $600M financing and $700M in commercial deals. Currently CEO of and Investor in Mogrify Ltd a pre-clinical stage biotechnology company developing a pipeline of in vivo reprogramming therapies that address chronic diseases of ageing using a systematic direct cell conversion & maintenance platform powered by big-data. Also Chairman of and investor in Celixir Ltd a clinical stage biotechnology company founded by Nobel Laureate Sir Martin Evans who are developing cell therapies for cardiovascular, oncology and orthopaedic indications. Previously was co-founder, investor and former CEO of gene editing company Horizon Discovery Group Plc (LSE: HZD) leading company from $200k seed-funding to a 2.5X oversubscribed $113M life science IPO on AIM and onto a peak market capitalization in excess of $550M returning 2X to 50X ROI. Avid believer in developing entrepreneurial talent supporting business plan competition and providing non-dilutive funding and mentoring programs via a 10-year endowment of the C R Lowe Carpe Diem Enterprise Fund. Projects supported recently include Cambridge University Entrepreneurs, HealX Ltd, Footprint Cafes CIO, MPhil in Bioscience Enterprise (Cambridge University) and SimPrints Ltd.Recognition (selected):Officer of the Most Excellent Order of the British EmpireLifetime Queens Award for Enterprise Promotion European Life Science Business Leader of the Year UK Quoted Company Entrepreneur of Year UK Public Life Science CEO of Year Barclays Iconic UK Male EntrepreneurScrip AwardsBest Licensing DealExecutive of Year Business Excellence AwardsBusiness Person of YearTimes/Maserati 100 Disruptive UK Entrepreneurs Cambridge's 25 Most Influential 100 Faces of a Vibrant UK EconomyRoyal Society of Chemistry175 Faces of Chemistry
Roquefort Therapeutics Plc
View- Website:
- roquefortplc.com
- Employees:
- 3
-
Interim Managing Director And DirectorRoquefort Therapeutics PlcUnited Kingdom
-
Non Executive DirectorRoquefort Therapeutics Plc Sep 2022 - PresentLondon, GbRoquefort Therapeutics plc was established to acquire businesses focused on early-stage drug development opportunities in the medical biotechnology sector with the aim of developing a pipeline of therapies that ultimately generate optimal returns for both the target businesses and our shareholders.Roquefort is listed on the main market of the London Stock Exchange under the ticker ROQ.
-
Advisory Board MemberSana Capital Jul 2022 - PresentCambridge, Cambridgeshire, GbAdvisory board member of Sana Capital a new, female-led investment fund supporting innovation in science and technology that will drive positive change in human healthcare. -
Ceo, Director & InvestorMogrify Jan 2019 - PresentCambridge, Cambridgeshire, GbCEO responsible for corporate strategy, execution and governance. Mogrify has developed a proprietary systematic data-science driven cell conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the key transcriptomic and/or epigenetic switches that control human cell fate. Mogrify is applying its technology to generate IP and cell conversions that will power the development and manufacture of a new class of in vivo reprogramming therapies for chronic degenerative diseases of the ear, eye, pancreas and lung.Seed/A/Grant funding of $50M raised in 2019/20/21/23. -
Chairman, Director & InvestorCelixir Sep 2015 - PresentCardiff, Wales, GbInvestor and Chairman of the Board of Directors of regenerative medicine company founded by Nobel Prize winner for Sir Martin Evans. Phase 2 clinical trial stage with lead HeartCel product plus oncology and orthopaedic cell therapy assets.Funding of c$30M raised in 2015/22, Contingent PIPE funding of $100M in place.Demerged oncology pipeline acquired by Roquefort Therapeutics Plc in September 2022 -
Principal & FounderCarpe Diem Investment Fund Jan 2008 - PresentInvestor in portfolio of companies in IT, Tech and Life Science sectors.
-
Chairman Of Trustees & DonorFootprint Cafes Cio Apr 2016 - Jul 2023Footprint Cafés is a triple-lock social enterprise that is undertaking an audacious but achievable mission of building a chain of sustainable Enterprise Cafés that break down barriers to education and deliver impacting change to local communities.Founded by Georgina Hemmingway the enterprise builds on the success of over the past three years New Leaf Book café in Cambodia which now employs 17 staff and has generated and donated 100% of its profits to eight local organizations tackling illiteracy, gender inequality and community development.
-
Honorary Visiting Fellow, School Of Environmental And Life SciencesThe University Of Salford Apr 2017 - Oct 2022Salford, Greater Manchester, GbHonorary Visiting Fellow of The School of Environmental and Life Sciences. Providing strategic and industrial context to researchers as well as access to networks in Life Sciences. Ambassadorial role promoting the activities of the School. -
Honorary Fellow In EntrepreneurshipCambridge Judge Business School Jul 2016 - Oct 2022Cambridge, GbHonorary Fellowship supporting the research, teaching, fundraising and ambassadorial activities of the school. -
Entrepreneur In ResidenceCambridge Judge Business School Sep 2012 - Aug 2016Cambridge, GbInvited lecturer, course content provider and mentor on various higher education programs and courses.
-
Enterprise Fellow, Department Of Chemical Engineering & BiotechnologyUniversity Of Cambridge Sep 2013 - Oct 2022Cambridge, England, GbInvited lecturer and mentor at the Department of Chemical Engineering and Biotechnology. -
Principal & FounderCarpe Diem C R Lowe Enterprise Fund Sep 2011 - Aug 2021Award of needs based bursaries and hardship grants, funding, mentorship, student entrepreneurship activities (Cambridge University Entrepreneurs, Cambridge University Technology and Enterprise Club) and emerging start-up companies.
-
Board MemberBioindustry Association Oct 2015 - Sep 2018London, GbElected board member of organisation whose mission is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. The BIA binds the community together, serving as its voice with stakeholders, lobbying government and regulatory bodies, building connections between individuals and organisations, helping to shape the future of bioscience. -
Director & MentorHealx Mar 2015 - Jun 2018Cambridge, Cambridgeshire, GbAdvisor on commercial and operations strategy to company using AI driven platform to intelligently match drugs to patients of rare diseases. Winner CR Lowe Carpe Diem Enterprise Life Science Start-up of Year 2015; Seed Funding of c$500k raised 2015; Series A Funding of C$13M raised 2016, 2018. Series B Funding of $55M raised in 2019. -
Trustee And Executive Council MemberCambridge Science Centre Jan 2015 - Jun 2018Cambridge, England, GbMember of not-for-profit Board that both guides organizational direction and supports financially the Cambridge Science Center an exhibition centre that works locally and regionally (via mobile exhibitions) to engage children and families through hands on science exhibits, shows and workshops. -
Advisory Board MemberSimprints Jan 2015 - Jun 2018Cambridge, Cambridgeshire, GbAdvisor on commercial and operational strategy to Social Enterprise.Winner of CR Lowe Enterprise Funded Cambridge University Entrepreneurs Social Enterprise of the Year 2014.Seed Funded by Arm and Bill and Melinda Gates Foundation and various grant bodies. $8M raised. -
Advisory Board Member And InvestorAxol Bioscience Ltd. Jan 2015 - Jun 2018Cambridge, Cambridgeshire, GbAdvisor on corporate development, business strategy and investor relations for company operating in the reprogramming of stem cells to create novel research tools. Investor.Co-lead investor on Series A Funding Raised of £1M in 2016.Series B Raised of £3M in 2017. -
Advisory Board MemberBiotech And Money Ltd. Nov 2014 - Jun 2018London, London, GbMember of board advising publication that aims to provide closer ties between bioscience, investors, pharma, financiers, customers, legal and professional advisers. -
Investor, MentorBitbio Mar 2016 - Mar 2018Seed Investor and mentor to founder of UK biotechnology company engaged in the use of a proprietary cell reprogramming platform to create consistent, pure and evergreen supply of primary human cell types.£300k seed (2016); £6M Seed Extension (2019); £30M A (2020); £65M B (2021) -
Co Founder, Executive ChairmanAvvinity Therapeutics Limited Feb 2016 - Feb 2018Established as a joint-venture between Horizon Discovery Group Plc and Centauri Therapeutics Avvinity is developing novel cancer immunotherapies based on proprietary Alphamer technology invented by Cary Mullis, Nobel Prize winner for invention of PCR. £3M seed funding committed in 2016.
-
Chief Executive Officer And Co-FounderHorizon Discovery Jul 2007 - Feb 2018Cambridge, Cambridgeshire, GbCEO of global life science company supplying research tools, contract research services and novel research programs that impact translational genomics research, personalized medicine and cell therapy.Pre-IPO Funding c$30M Raised 2008-2013; Post IPO Funding c$180M (Primary) and c$90M (Secondary) placements. Market Capitalization high in 2017 of c$560M. Has delivered 2X to 50X return on investment for investors. -
Chairman, Co-Founder & InvestorGeospock Ltd. Feb 2013 - Jan 2018Cambridge, GbAdvisor on corporate development, business strategy and investor relations. Lead Investor Seed and A Round.Winner CR Lowe Carpe Diem Enterprise Young Entrepreneur of the Year (Steve Marsh) of Year 2012; Seed Funding Raised of $2.5M in 2013-14Series A Funding Raised of $40M in 2015-2020. Chairman Feb 2013 to Sept 2016Non-Executive Director Feb 2013 to Nov 2017 -
Chairman And InvestorDesktop Genetics Jul 2013 - Nov 2017Cambridge, Massachusetts, UsAdvisor on corporate development, business strategy and investor relations. Lead Investor Seed Round.Winner CR Lowe Carpe Diem Enterprise Life Science Start-up of Year 2012; Seed Funding of $3M raised over 2013/2015. -
Ceo And Co-FounderAdaptive Profiling Limited Nov 2000 - Jun 2002CEO and co-founder of biotech company with Scientific Generics Plc, Imperial College and University of Glasgow. Company engaged in R&D aimed at developing protein array, cell chip and predictive bioinformatics platform to enable the implementation of advanced molecular profiling of drug candidates.c$2M funding raised 2001-02
-
Bioscience ManagerTtp Group Plc Feb 1998 - May 2000Melbourn, Hertfordshire, GbResponsible for managing the Bioscience R&D program of the Acumen High Content Screening consortia comprising and funded by AstraZeneca, Aventis and TTP. Along with senior leadership raised non-dilutive funding of the program and headed the successful launch of the Acumen Explorer in 2000, a platform that still sells today (sold to Danehar 2019).
Dr Darrin M Disley Obe Skills
Dr Darrin M Disley Obe Education Details
-
University Of CambridgeBiotechnology -
The University Of SalfordEnterprise And Healthcare
-
The University Of SalfordChemistry
-
City Of Westminster CollegeScience
-
Bedfords Park ComprehensiveNo Qualifications Obtained.
Frequently Asked Questions about Dr Darrin M Disley Obe
What company does Dr Darrin M Disley Obe work for?
Dr Darrin M Disley Obe works for Roquefort Therapeutics Plc
What is Dr Darrin M Disley Obe's role at the current company?
Dr Darrin M Disley Obe's current role is Interim Managing Director and Director.
What is Dr Darrin M Disley Obe's email address?
Dr Darrin M Disley Obe's email address is da****@****xir.com
What is Dr Darrin M Disley Obe's direct phone number?
Dr Darrin M Disley Obe's direct phone number is +4412236*****
What schools did Dr Darrin M Disley Obe attend?
Dr Darrin M Disley Obe attended University Of Cambridge, The University Of Salford, The University Of Salford, City Of Westminster College, Bedfords Park Comprehensive.
What are some of Dr Darrin M Disley Obe's interests?
Dr Darrin M Disley Obe has interest in Popular Music, Start Ups, Economic Empowerment, Rugby, Civil Rights And Social Action, Politics, Education, Scuba, Jazz, Cricket.
What skills is Dr Darrin M Disley Obe known for?
Dr Darrin M Disley Obe has skills like Biotechnology Industry, High Tech, Software, Entrepreneurship, Education, Mobile Applications, Investment Advisory, Angel Investing, Management, Board Of Directors, Corporate Development, Business Planning.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial